InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | 2026-05-04 | Heshmatpour Amir F | Director & President | Purchase | 10.0K | $4.16 | $42K | 3.07M | View ↗ | |
| 2026-04-28 | 2026-04-28 | Heshmatpour Amir F | Director & President | Purchase | 10.0K | $4.52 | $45K | 3.06M | View ↗ | |
| 2026-04-23 | 2026-04-24 | Neman-Ebrahim Yousha | Chief Clinical Officer | Purchase | 500 | $4.88 | $2K | 134.8K | View ↗ | |
| 2025-04-15 | 2026-04-24 | GARNETT KEITHLY | CFO | Purchase | 300 | $5.38 | $2K | 241.2K | View ↗ | |
| 2026-04-23 | 2026-04-23 | Heshmatpour Amir F | Director & President | Purchase | 10.0K | $4.90 | $49K | 3.05M | View ↗ |
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $40K-51.8% | $83K |
| Research and development | $3.6M+19.5% | $3.0M |
| Legal and professional | $2.5M+24.0% | $2.0M |
| General and administrative | $4.8M+186.8% | $1.7M |
| Share based compensation | $35.6M | — |
| Advisory fees – principally related parties | $11.8M+2257.6% | $500K |
| Total Operating Expenses | $58.3M+706.6% | $7.2M |
| Loss From Operations | -$58.2M-715.4% | -$7.1M |
| Interest and other income | $328K+1930.5% | $16K |
| Grant income | $71K | — |
| Amortization of debt issuance costs | -$1.1M-665.3% | -$145K |
| Interest expense | -$2.5M+2.1% | -$2.6M |
| Loss on extinguishment of Bridge loan – related party | -$2.1M | — |
| Loss on change in fair value of derivative liability related to sales of common stock through equity line of credit | -$690K | — |
| Net Loss | -$62.1M-422.3% | -$11.9M |
| Basic net loss per common share | -$3.2-363.8% | -$0.69 |
| Diluted net loss per common share | -$3.2-363.8% | -$0.69 |
| Weighted average shares used in computing basic net loss per common share | $19.4M+11.9% | $17.3M |
| Weighted average shares used in computing diluted net loss per common share | $19.4M+11.9% | $17.3M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics (NASDAQ:VVOS)
NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results
NeOnc Provides Business Update and Reports Q4 2025 Financial Results
NeOnc Technologies Appoints David Choi as Chief Accounting Officer
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
NeOnc Technologies Holdings GAAP EPS of -$0.45
NeOnc Technologies: From Survival Mode To Expansion Mode
NeOnc Technologies Holdings GAAP EPS of $0.30
NeOnc Technologies signs agreement for $50M partnership with Quazar Investment